Search Results - TherapeuticArea

3 Results

Sort By:

EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...

Published: 7/2/2025 | Inventor(s): Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo

Keywords(s):

Category(s): Application, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K

Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01. Description of Technology: Phosphatidylinositol-4,5-biphosphate...

Published: 5/14/2025 | Inventor(s): Steven Rosenberg, NIkolaos Zacharakis, S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank Lowery

Keywords(s):

Category(s): TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use

Summary: The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research. Description of Technology: Tumor-specific mutated proteins can create immunogenic, mutation-containing “neoepitopes” which are attractive...

Published: 4/22/2025 | Inventor(s): Catherine Ade, Zhiya Yu, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s):

Category(s): TherapeuticArea, Application, Application > Research Materials, Collaboration Sought > Licensing